市場調查報告書

體外診斷品質管理的全球市場:成長,趨勢,預測(2020年∼2025年)

In-Vitro Diagnostics Quality Control Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 925297
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
體外診斷品質管理的全球市場:成長,趨勢,預測(2020年∼2025年) In-Vitro Diagnostics Quality Control Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球體外診斷(IVD)品質管理市場在2020年∼2025年間,預測將以約3.5%的年複合成長率成長。市場成長的主要原因,是全球感染疾病,HIV,及癌症的擴大,那些為了有效率的治療需要新的診斷方法及監視那些的性能的品質管理。譬如,根據HIV與AIDS相關共同聯合國計劃(UNAIDS),2019年,HIV感染者有2,450萬人在全世界利用抗逆轉錄病毒療法。為了控制感染疾病發生的政府參加的增加,及即時診斷系統與品質評估支援的需求高漲,預計在預測期間內推動全球市場成長。

本報告提供全球體外診斷品質管理市場的相關調查,市場機會和趨勢,成長及阻礙因素,各市場區隔和各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 為了機密報告與正確診斷的先進診斷的需求增加
    • 感染疾病,癌症,遺傳性疾病的全球發生率上升
    • 認定的臨床檢驗室的增加和第三方的品質管理的採用
  • 阻礙市場要素
    • 對IVD產業的不利償付方針
    • 新興經濟國的臨床檢驗室認證缺乏嚴格法規
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔

  • 各產品及服務
    • 品質管理產品
    • 資料管理解決方案
    • 品質保證服務
  • 各用途
    • 免疫化學
    • 血液學
    • 分子診斷
    • 凝固/止血
    • 其他
  • 各終端用戶
    • 醫院
    • 臨床檢驗室
    • IVD廠商和CRO
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc
    • F. Hoffmann-La Roche AG
    • Quidel Corporation
    • bioMerieux Inc
    • Qnostics Ltd
    • Microbiologics Inc
    • SeraCare Life Sciences Inc
    • Thermo Fisher Scientific
    • ZeptoMetrix Corporation

第7章 市場機會及未來趨勢

目錄
Product Code: 67825

The In-Vitro Diagnostics (IVD) quality control market studied was anticipated to grow with a CAGR of nearly 3.5% during the forecast period. The major factors attributing to the growth of the market are a rise in the global prevalence of infectious diseases, HIV, and the cancers which necessitate novel diagnostic methods for efficient treatment and quality controls to monitor their performance. For instance, according to the Joint United Nations Programme on HIV and AIDS (UNAIDS), in 2019, 24.5 million people with HIV were accessing antiretroviral therapy globally. Additionally, increased participation of the government to control the outbreaks of infectious diseases and a rise in the demand for quality assessment support along with immediate diagnosis systems are expected to contribute to the growth of the global market during the forecast period.

Key Market Trends

Immunochemistry segment in the Application is Expected to Hold the Largest Market Share in the In Vitro Diagnostics Quality Controls Market

  • Immunochemistry diagnostics are anticipated to hold the largest market share in the IVD quality controls market due to their importance in identifying the molecular mechanism of various antigens, antibodies, and their interactions that impact the immune system. The increased demand for the segment is owing to a rise in the prevalence of various autoimmune disorders, infections, communicable and chronic diseases among all the age groups in recent years necessitating earlier diagnosis with more accuracy and precision for better treatment are fueling the growth of the market.
  • On the other hand, the molecular diagnostics segment is anticipated to witness the highest CAGR over the forecast period due to a rise in the adoption of advanced technologies such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS). Furthermore, an increased application of molecular diagnostics in the diagnosis of cancers with a rising global prevalence of cancer, increasing research on cancer biomarkers, advanced diagnosis infrastructure and other applications in detecting multiplex PCR, HIV, respiratory tract infections and genital infections propelling the global market revenue.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall In Vitro Diagnostics quality controls market, throughout the forecast period. The high adoption rate of advanced infrastructure, increased number of diagnostic centers and accredited clinical laboratories are factors estimated to fuel the market in the region. In North America, the United States holds the largest market share due to increased patient pool. For instance, as per U.S. Department of Health & Human Services report published in 2020, about 37,832 people in the U.S. were diagnosed with HIV in 2018 and 38,000 new HIV infections still occur in the United States and 6 dependent areas each year which results in rapid spread of various infectious diseases such as meningitis, urinary tract infections fueling the market contributing its outstanding share of the global market revenue during the forecast period.

Competitive Landscape

The In Vitro diagnostics quality controls market is moderately competitive and consists of several major players. Some of the companies are expanding their market position by adopting various strategies such as acquisitions and mergers, while others are developing new methods for the treatment and introducing new products to maintain their market share. For instance, in April 2019, Bruker expanded its portfolio for microbial identification, infection control, and molecular diagnostics of infectious diseases by introducing new assays, software and library extensions for its MALDI Biotyper, IR Biotyper, and Fluorocycler XT product lines which is expected to have a positive impact on the market. Some of the companies which are currently dominating the market are Bio-Rad Laboratories Inc F. Hoffmann-La Roche AG, SeraCare Life Sciences Inc, bioMerieux Inc and ZeptoMetrix Corporation.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Demand for Advanced Diagnostics for Sensitive Reports and Accurate Diagnosis
    • 4.2.2 Rise in Global Incidence of Infectious Diseases, Cancers and Genetic Disorders
    • 4.2.3 Rise in the Volume of Accredited Clinical Laboratories and Adoption of Third-Party Quality Controls
  • 4.3 Market Restraints
    • 4.3.1 Unfavorable Reimbursement Policies for IVD Industry
    • 4.3.2 Lack of Stringent Regulations for Clinical Laboratory Accreditation in Several Emerging Economies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Products and Services
    • 5.1.1 Quality Control Products
    • 5.1.2 Data Management Solutions
    • 5.1.3 Quality Assurance Services
  • 5.2 Application
    • 5.2.1 Immunochemistry
    • 5.2.2 Hematology
    • 5.2.3 Molecular Diagnostics
    • 5.2.4 Coagulation/Hemostasis
    • 5.2.5 Others
  • 5.3 End Users
    • 5.3.1 Hospitals
    • 5.3.2 Clinical Laboratories
    • 5.3.3 IVD Manufacturers & CROs
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Bio-Rad Laboratories Inc
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 Quidel Corporation
    • 6.1.5 bioMerieux Inc
    • 6.1.6 Qnostics Ltd
    • 6.1.7 Microbiologics Inc
    • 6.1.8 SeraCare Life Sciences Inc
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 ZeptoMetrix Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS